Evidence links air pollution to dementia, yet its role in Lewy body dementia (LBD) remains unclear. In this work, we showed in a cohort of 56.5 million individuals across the United States that fine particulate matter (PM2.5) exposure raises LBD risk. ...

More than 1,000 patients to take part in trial to see if the approach leads to faster and more reliable diagnoses

The future of biomarkers and the importance of registers in dementia research

Your brain has its own elite defense team — and new research shows these "guardian" cells might be the real battleground for neurological diseases like Alzheimer’s and stroke. Scientists discovered that most genetic risks linked to these diseases act not in neurons, but in the blood vessels and immune cells that form the blood-brain barrier.

We're pleased to share Anna Maxted's thoughtful feature in The Times, published yesterday: "The dementia patients who could change lives". Her story captures the personal experiences of volunteers participating in the DPUK READ-OUT study, part of the Blood Biomarker Challenge. We're grateful to Beverley Evans and Stephanie Everill for generously sharing their stories with The Times. Their willingness to share their personal experiences helps us in reaching a wider audience to talk about the valuable research we are doing to bring blood biomarkers for dementia into common usage within the NHS.

A prominent Nature study and related research raise the possibility that vaccines may have a broader role in experimental therapeutics outside the realm of infectious diseases.

Clinical trial results showed that a lifestyle program incorporating physical exercise, diet, cognitive & social engagement, & health monitoring improves cognitive function.

Here the authors apply machine learning approaches to Alzheimer’s genetics, confirm known associations and suggest novel risk loci. These methods demonstrate predictive power comparable to traditional approaches, while also offering potential new insights beyond standard genetic analyses.

DPUK's READ-OUT study, part of the Blood Biomarker Challenge, has reached a major milestone with the commissioning of its 15th clinical site to the study. It now has half of its planned 30 sites operational, recruiting participants to the study.

A new drug could halt the progression of Alzheimer's disease - granting hope to thousands who suffer from the illness.